Related Experiment Video
Updated: Mar 22, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
Published on: March 15, 2016
Evolution of a New Class of VEGFR-2 Inhibitors from Scaffold Morphing and Redesign
Nello Mainolfi1, Rajeshri Karki1, Fang Liu2
1Global Discovery Chemistry, Novartis Institutes for Biomedical Research , 100 Technology Square, Cambridge, Massachusetts 02139, United States.
Abstract:
Anti-VEGF therapy is a clinically validated treatment for age-related macular degeneration (AMD). We have recently reported the discovery of oral VEGFR-2 inhibitors that are selectively distributed to the ocular tissues. Herein we report a further development of those compounds and in particular the validation of the hypothesis that aminoheterocycles such as aminoisoxazoles and aminopyrazoles could also function as effective "hinge" binding moieties leading to a new class of KDR (kinase insert domain containing receptor) inhibitors.
More Related Videos
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Mechanism of Angiogenesis
TGF - β Signaling Pathway
Non-Canonical Wnt Signaling Pathways

